#United States #New York #Class Action #deramiocel #Capricor

Capricor Therapeutics Investors Encouraged to Join Class Action Following Significant Losses

Capricor Therapeutics Class Action Notice

The Gross Law Firm has issued a crucial notice for shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) who faced losses due to recent developments regarding the company’s lead drug candidate, deramiocel. The firm encourages affected investors to participate in a class action lawsuit to seek recovery of their losses.

Background of Capricor Therapeutics

Capricor, a biopharmaceutical company, has been at the forefront of developing innovative treatments for serious medical conditions, including cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The firm's lead product, deramiocel, was expected to be a transformative option for patients. However, crucial events leading up to mid-July 2025 raised serious concerns regarding the company’s credibility and the viability of its product.

The Allegations

According to the recent complaint, Capricor's management allegedly provided misleading and overly optimistic information about deramiocel’s chances of obtaining a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA). These assertions were made during a period when the company was reportedly hiding damaging information regarding the safety and efficacy data from its Phase 2 HOPE-2 trial of the drug.

In particular, the allegations highlight that while the company communicated positivity about securing the BLA, it failed to disclose critical adverse facts about the results from its clinical trial, which would directly affect the drug's approval process.

Significant Stock Price Decline

On July 11, 2025, Capricor announced that it had received a Complete Response Letter (CRL) from the FDA denying its BLA for deramiocel. The letter cited a failure to meet the stringent requirements for demonstrating substantial effectiveness and pointed out the need for additional clinical data. The fallout was immediate; the stock price plummeted from $11.40 per share to $7.64 in just one day, causing substantial losses for shareholders who had invested during the class period from October 9, 2024, to July 10, 2025.

Call to Action for Investors

Shareholders who believe they have been impacted are strongly urged to join the class action by registering their details with the Gross Law Firm. This registration will not only validate their claims but also enable them to stay informed about the lawsuit's progress through dedicated portfolio monitoring software. The deadline for registering to participate in this class action is September 15, 2025, making it imperative for affected investors to act swiftly.

Why Choose The Gross Law Firm?

The Gross Law Firm has established itself as a prominent name in class action lawsuits concerning stockholder rights. The firm aims to protect the interests of all investors who have been misled or defrauded. Their commitment lies in ensuring that companies practice transparency and accountability, upholding their duty to their investors.

For more information or to get involved, shareholders are encouraged to contact the Gross Law Firm directly through the provided links, ensuring they do not miss the opportunity for potential recovery.